Home
>
National Drug Code (NDC)
>
Tazicef
Tazicef - 0409-5093-51 - (CEFTAZIDIME)
Drug Information of Tazicef
| Product NDC: | 0409-5093 |
| Proprietary Name: | Tazicef |
| Non Proprietary Name: | CEFTAZIDIME |
| Active Ingredient(s): | 2 g/1 & nbsp; CEFTAZIDIME |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Tazicef
| Product NDC: | 0409-5093 |
| Labeler Name: | Hospira, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA064032 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120305 |
Package Information of Tazicef
| Package NDC: | 0409-5093-51 |
| Package Description: | 10 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-5093-51) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM |
NDC Information of Tazicef
| NDC Code | 0409-5093-51 |
| Proprietary Name | Tazicef |
| Package Description | 10 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-5093-51) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM |
| Product NDC | 0409-5093 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CEFTAZIDIME |
| Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20120305 |
| Marketing Category Name | ANDA |
| Labeler Name | Hospira, Inc. |
| Substance Name | CEFTAZIDIME |
| Strength Number | 2 |
| Strength Unit | g/1 |
| Pharmaceutical Classes | Cephalosporin Antibacterial [EPC],Cephalosporins [Chemical/Ingredient] |
